What Percentage of Positive FIT Tests Are Cancer?

Roughly two to five percent of positive fecal immunochemical test (FIT) results turn out to be colorectal cancer, depending on the screening program, the population tested, and the hemoglobin threshold the lab uses to define “positive.” That means the vast majority of people who get a positive result will not have cancer. But the number is far from meaningless, because what a positive FIT does find, even when it is not cancer, often matters a great deal for your long-term health.

How Often a Positive FIT Means Cancer in Real Screening Programs

The figure doctors call the “positive predictive value” (PPV) tells you what fraction of people with a positive test actually have the disease. For FIT-based colorectal cancer screening, the PPV for cancer specifically is consistently low across large programs. A national bowel cancer screening program using a FIT threshold of 20 micrograms of hemoglobin per gram of stool found that about 4.75% of people with a positive result had colorectal cancer.¹ A study looking at system-level screening at a standard cut-off found a PPV for cancer of about 2.4%.² In symptomatic patients referred for investigation, the number can climb higher: one cohort found a PPV of about 11% among people who tested positive on FIT.³

The spread between two and eleven percent is wide, and it reflects something important: context changes the odds. Average-risk adults going through a routine screening program have a different baseline cancer risk than people who already have symptoms like rectal bleeding or unexplained weight loss. A small Italian cohort of average-risk individuals found cancer in about 17.5% of those who went on to colonoscopy after a positive FIT, though the study involved fewer than 90 positive results and the percentage shifts easily in small samples.⁴ In general, if you are in a routine screening program with no symptoms, the likelihood that your positive FIT means cancer sits somewhere in the low single digits.

What Positive FIT Results Usually Do Find

If roughly 95 out of 100 people with a positive FIT do not have cancer, what is going on with them? Most of the clinically significant findings fall into one category: precancerous polyps. These are growths in the colon or rectum that have not yet turned into cancer but, left alone, could eventually do so. Among FIT-positive patients who went on to colonoscopy, one study found that 86% had at least one precancerous polyp, and about 31% had what is classified as an advanced adenoma, the type most likely to progress.⁵ Catching and removing these polyps is the whole point of screening. You find the problem before it becomes cancer.

A study comparing single versus double positive FIT results reinforced this pattern: polyp detection was substantially higher in the group that tested positive on two consecutive FIT kits compared with those positive on just one, with polyps found in about 60% of the double-positive group versus 42% of the single-positive group.⁶ This matters because it suggests that people with stronger or more consistent signals from FIT tend to harbor more significant findings at colonoscopy, even when those findings are not yet cancer.

The Hemoglobin Number on Your Test Changes the Odds

FIT is not simply a pass/fail test. Modern quantitative FIT kits measure how much hemoglobin is in your stool sample, and that concentration level can tell your doctor something about how worried to be. A large study found that the PPV for cancer rose from under 1% in people whose hemoglobin reading was in the 20–40 microgram range up to about 6.7% when the reading was 200 or above.⁷ Research on organized screening programs found a similar pattern, with hemoglobin levels of 200 or higher carrying nearly seven times the odds of cancer compared to results just above the positive threshold.⁸ The relationship between concentration and cancer risk follows a consistent upward pattern, with higher hemoglobin readings tied to more advanced findings.⁹

In one symptomatic cohort, more than half of the cancers found had FIT values above 400 micrograms per gram, while only about a fifth had values in the 11–50 range.³ So if your result just barely crossed the positive line, your individual risk of cancer is lower than the overall PPV figure would suggest. If the number was sky-high, your doctor has more reason for urgency.

Why the Threshold for “Positive” Changes Everything

Not all labs and screening programs use the same cut-off. Some programs call a result positive at 10 micrograms of hemoglobin per gram of stool, others at 20, and some at even higher levels. This choice has a direct trade-off: lower thresholds catch more cancers but also flag more people who turn out to be fine.

A community-based cohort study showed this clearly. Lowering the threshold from 20 to 10 micrograms per gram boosted the proportion of cancers detected from about 74% to about 79%, but it also roughly doubled the number of colonoscopies needed for each cancer found, jumping from 52 to 85 colonoscopies per cancer case.¹⁰ A systematic review and meta-analysis found that sensitivity for cancer detection rose from about 69% at a threshold between 10 and 20 to about 80% at a threshold of 10 or below, while specificity only dropped modestly, from about 94% to 91%.¹¹

Research has also explored whether the ideal cut-off should vary by age and sex. One study found that optimal thresholds differed between men and women and across age brackets, reflecting the fact that men with colorectal cancer tend to have somewhat higher hemoglobin concentrations in their stool than women with the same disease.¹² These tailored thresholds could, in theory, improve cancer detection in women without dramatically increasing the number of unnecessary colonoscopies in men. Most screening programs have not yet adopted sex-specific cut-offs, but the research is moving in that direction.

Non-Cancer Causes of a Positive Result

FIT detects human hemoglobin in stool. Cancer and precancerous polyps bleed, but they are not the only things that do. Hemorrhoids are the most commonly discussed culprit. A study of nearly 4,000 screening participants found that people with hemorrhoids had significantly higher rates of false-positive FIT results, with adjusted odds roughly 2.8 times higher than those without hemorrhoids.¹³ Among participants whose only finding was hemorrhoids, the false-positive rate was about 15%, compared to about 3% in people with no abnormality at all.

Diverticular disease (small pouches in the colon wall that can occasionally bleed) is another well-known source of occult blood in the stool. Other non-cancerous conditions that can cause a positive FIT include inflammatory bowel disease, ulcers, and angiodysplasias (abnormal blood vessels in the gut lining). A positive result, in short, means blood was found. It does not tell you where the blood came from.

Do Blood Thinners Cause False Positives?

This is one of the most common questions people ask when they get a positive FIT while taking aspirin, warfarin, or a newer anticoagulant. The worry makes intuitive sense: if these drugs make you bleed more easily, maybe the test is picking up drug-related bleeding rather than something in the colon. The evidence, however, is reassuring. A systematic review and meta-analysis found that neither oral anticoagulants nor aspirin or NSAIDs significantly altered the predictive value of FIT. The PPV for advanced neoplasia was essentially the same in users and non-users.¹⁴ A separate systematic review reached the same conclusion: anticoagulant use was the most frequently studied medication-related variable, and no significant effect on FIT positivity was found.¹⁵

A more recent analysis confirmed this picture: even though a slightly higher proportion of patients on antiplatelet or anticoagulant therapy tested positive, the difference was not statistically significant, and the false-positive rates and PPV were similar between exposed and unexposed groups.¹⁶ Current guidance does not recommend stopping blood thinners before FIT screening.

When FIT Misses a Cancer

No screening test is perfect, and FIT does sometimes return a negative result in someone who has colorectal cancer. These are called interval cancers, cancers that surface between screening rounds after a negative test. A systematic review estimated the pooled incidence of interval cancers following FIT at about 20 per 100,000 person-years. For every interval cancer, there were about 2.6 cancers detected by the FIT screening itself, meaning the test catches the substantial majority.¹⁷

Several factors influence how likely FIT is to catch a cancer. Sensitivity was higher at lower thresholds: about 90.5% when the cut-off was set low versus 83% at a higher cut-off. Men with cancer were identified with slightly higher sensitivity than women, about 87% versus 83%.¹⁸ This sex difference is thought to relate to the types and locations of tumors more common in women, some of which bleed less than the average colorectal cancer.

FIT also performs differently over multiple screening rounds. Sensitivity is highest in the first round, around 84.5%, and settles to roughly 73–78% in subsequent rounds.¹⁹ This is not because the test degrades. The first round catches a backlog of prevalent cancers that have been growing silently for years. Once those are removed, subsequent rounds are looking for newer, smaller lesions that may not bleed as consistently. Over time, long-term participation in screening reduces cancer risk, but the PPV for cancer in later rounds drops below what you see in first-time screeners.²⁰

How FIT Compares to the Older Guaiac Test

Before FIT, the standard stool screening test was the guaiac-based fecal occult blood test (gFOBT), which relied on a chemical reaction to detect blood rather than using antibodies specific to human hemoglobin. FIT is substantially more sensitive. A Cochrane systematic review found that FIT detected cancer with a sensitivity of about 65–76% at common thresholds, compared to about 39% for gFOBT.²¹ FIT also produces fewer false positives from dietary sources like red meat, because it specifically targets human hemoglobin. The PPV of FIT for cancer detection was roughly three times higher than that of gFOBT in a hospital-based comparison.²² If you have been offered FIT as your screening method, it represents a meaningful upgrade over what was available a generation ago.

Why You Should Not Wait Too Long for Your Colonoscopy

Once you have a positive FIT, the next step is almost always a colonoscopy to look directly at the lining of the colon. How quickly you get that colonoscopy matters. A large study of over 70,000 patients found that getting the colonoscopy within six months of a positive FIT carried no significant increase in cancer risk compared with getting it within the first month. But waiting ten to twelve months was associated with about a 48% higher risk of cancer being found, and more than double the risk of advanced-stage disease at that point.²³ Beyond twelve months, the picture worsened sharply, with the odds of advanced-stage disease roughly tripling.

A systematic review pooling several studies confirmed the pattern: colonoscopy performed beyond nine months from a positive FIT was consistently linked with more cancer diagnoses and more advanced stages at diagnosis.²⁴ A study of over 200,000 US veterans found that delaying colonoscopy by 19 to 24 months was associated with 1.4 to 1.5 times the risk of dying from colorectal cancer, compared with getting the follow-up within three months.²⁵ The practical message is clear: scheduling delays of a few weeks are unlikely to change your outcome, but letting months pass before follow-up can have real consequences.

A Positive FIT Can Also Signal Non-Colorectal Cancers

FIT is designed to detect colorectal problems, but hemoglobin in stool can originate anywhere along the digestive tract. A study from Taiwan tracked people who tested positive on FIT but were found not to have colorectal cancer, and compared their rates of upper gastrointestinal cancers to people who tested negative. Those with a positive FIT but no colorectal cancer had elevated risks of esophageal, stomach, and small intestine cancers in the years following the test.²⁶ This does not mean FIT is a reliable screening test for stomach or esophageal cancer, but it suggests that an unexplained positive FIT, where colonoscopy finds nothing concerning, may warrant attention to upper gastrointestinal symptoms as well.

Sample Handling Can Skew Your Result

One underappreciated variable in FIT accuracy is what happens to the sample between collection and analysis. Hemoglobin in stool degrades over time, especially in heat. Studies have shown that hemoglobin concentrations drop significantly when samples are stored at room temperature versus refrigeration, and the decline accelerates in warmer conditions.²⁷ In one experiment, hemoglobin remained above 80% of its initial level for about 20 days at room temperature with an improved buffer formulation, but only six days with an older formulation. At higher temperatures the window shrank to just a few days.²⁸

What this means for you: if you collect a FIT sample during hot weather and leave it sitting in a mailbox or a warm car for several days before mailing it, the hemoglobin in the sample may degrade enough to push a positive result below the detection threshold. Keeping the sample cool and returning it to the lab promptly reduces the chance of a false negative.

The Anxiety Between a Positive Test and Colonoscopy

Finally, it is worth acknowledging that the waiting period between a positive FIT and the colonoscopy that follows is psychologically difficult for many people. Qualitative research with screening participants has documented substantial anxiety, sadness, and intrusive thoughts during this window, even among people who considered themselves healthy and had participated in the program routinely.²⁹ Understanding the actual numbers can help put the result in perspective: in most screening populations, a positive FIT has well under a one-in-ten chance of meaning cancer, and the most common finding at colonoscopy is a polyp that can be removed on the spot before it ever becomes dangerous.

FIT Versus Newer and Costlier Screening Tests

Stool DNA tests, blood-based screening tests, and CT colonography have all entered the market, often with marketing that positions them as upgrades over FIT. From a cost-effectiveness standpoint, annual FIT remains hard to beat. Modeling studies have found that FIT-based screening is the only strategy among common options that actually produces net cost savings over a lifetime, while also yielding the largest quality-of-life gains when adherence is accounted for.³⁰ Blood-based tests, by comparison, yielded the fewest quality-adjusted life years gained and the highest net costs under realistic adherence assumptions. A separate analysis found that while alternative tests can play a role for people who refuse both FIT and colonoscopy, stool DNA screening and blood tests carry higher costs per additional cancer found.³¹ The appeal of a simple blood draw is real, but for now the humble stool test delivers the best overall screening value for average-risk adults.